On the stock market since 2022, it operates in the world of money and finance. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Red columns mark years that ended in a loss.
The stock trades 55% below its peak. The market has trimmed its expectations for the company.
Over the last 12 months, company executives reported 2 buys and 0 sells. Management buying with its own money is usually read as a good sign.
A loss of $554K against $0 in annual sales.
The stock sits at $0.09. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
On our five-subject report card, MSSAR sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: MSSAR is a high-risk stock — not yet profitable, and its future rides on its product catching on.